Dr.Reddy's Laboratories LtdNYSE:RDY
Symbol Lookup
Refresh
Recent News»
0 New Today| Company | Market Cap | P/E Ratio (TTM) | EPS Growth (5yr) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United-Guardian Inc UG | 118.5M | 22.9x | +8.68% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Eisai Co Ltd ESALY | 13.0B | 26.9x | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cumberland Pharmaceuticals Inc CPIX | 91.1M | 15.4x | +3.90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Pernix Therapeutics Holdings Inc PTX | 121.8M | -- | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Columbia Laboratories Inc CBRX | 56.8M | 9.1x | -- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Data delayed 15 minutes. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Company Information
Dr. Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company. The Company operates in three segments: Global Generics segment, which includes its prescription and over-the-counter (OTC) drug products business; Pharmaceutical Services and Active Ingredients (PSAI) segment, which consists of its active pharmaceutical ingredients (API) business and custom pharmaceutical services (CPS) business, and Proprietary Products segment, which consists of DRL's new chemical entities (NCEs) business, its Differentiated Formulations business and its dermatology focused specialty business operated through Promius Pharma. On March 27, 2012, DRL launched quetiapine fumarate tablets. On March 2, 2012, it launched ziprasidone hydrochloride capsules. On October 24, 2011, DRL launched olanzapine tablets. On July 25, 2011, it launched fondaparinux sodium injection.
| Headquarters | Door No 8-2-337 Road No 3, Banjara Hills HYDERABAD, India 500034 |
|---|---|
| Phone | 404-900-2900 |
| Fax | 404-900-2999 |
EXECUTIVE OFFICERS
| Executive Chairman of the Board, Chief Executive Officer | G. Prasad |
|---|---|
| Executive Vice Chairman of the Board, Chief Operating Officer, Managing Director | Satish Reddy |
| Chief Financial Officer, President, Global Head - Quality, HR and IT | Saumen Chakraborty |
| President - Pharmaceutical Services and Active Ingredients | R. Ananthanarayanan |
| President - Global Generics | Abhijit Mukherjee |
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
Open a New Account, or Login if you're a client.
(GAAP)*
| Market Cap | $6.4B | Beta | 1.05 |
|---|---|---|---|
| Revenue (TTM) | $2.0B | EPS | $1.55 |
| Shares Out. | 169.8M | Book Value | $6.17 |
| Dividend Yield | 0.65% | P/E | 24.4x |
| Annual Dividend Rate | $0.25 | Price/Sales (TTM) | 3.2 |
| Ex-Div Date | 6/27/12 | P/Cash Flow (TTM) | 17.7x |
| Pay Date | 6/27/13 | Operating Margin | 16.31% |
*GAAP = prior to non-GAAP analyst adjusted earnings.
(Non-GAAP)*
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
